DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

Tc-99m generator production resumes in Australia Follows month and a half shutdown due to conveyor belt issue

Sotera Health's Nordion closes sale of medical isotopes business to BWX Technologies About 150 employees will be transferred in the deal

Cerveau Technologies to expand production network for research on novel tau imaging agent Understanding Alzheimer's with [18F]MK-6240

GE Healthcare, Lantheus start second Flurpiridaz phase 3 clinical trial Evaluating PET agent's ability to detect CAD

New technologies to help expand PET/CT imaging in emerging markets Insights from Rick Rippin, sales director for ABT Molecular Imaging

RadioMedix and ITM greenlight Ge-68/Ga-68 generator production at new Texas facility Reducing global shortage of Ge-68/Ga-68 generators

First order of NorthStar's RadioGenix System in the books Comes alongside FDA clearance of its Wisconsin facility

SNMMI and others urge Congress to approve $20 million for U.S. supply of Mo-99 Funding would be provided for NNSA's medical isotope program

Low-risk patients subject to costly, unnecessary breast imaging, says study Ranges from $2,000 to $8,000, creates high-deductible burdens

ITM enters North American partnerships to establish stable n.c.a.-Lutetium-177 supply Enhance use and supply for targeted radionuclide therapy

NOPR and others urge CMS to reconsider NaF PET coverage

John R. Fischer , Staff Reporter
Patients prescribed a PET scan with 18F-sodium fluoride will still have to dip into their own pockets following the Centers for Medicare and Medicaid Services’ rejection of a request to reconsider covering the contrast agent.

Written and signed by the National Oncologic PET Registry (NOPR) working group, the request called for CMS to reevaluate its National Coverage Determination for NaF PET on the basis that the substance provided more appropriate forms of care to patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"The NOPR data clearly show that use of NaF PET led to more appropriate care for many cancer patients. We urge CMS to reconsider coverage for these potentially lifesaving and life-improving exams," NOPR principal investigator Dr. Bruce Hillner, said in a statement.

Following its closure of NOPR in December 2017, CMS chose to restrict reimbursements for the use of NAF PET in detecting cancerous bone metastases, asserting that such scans are “not reasonable and necessary to diagnose or treat an illness or injury or to improve the functioning of a malformed body member,” in a memo.

The agency agreed to continue reimbursing NaF-18 PET with evidence development programs for 24 months as it awaited the publication of evidence in The Journal of Nuclear Medicine, the findings of which ultimately supported the notion that the contrast agent offers more appropriate palliative and curative care in patient management.

The peer-review journal also approved of its use in 2016 as part of a pilot study that associated it with better clinical outcomes and patient survival.

Backing the NOPR proposal is the Society of Nuclear Medicine and Molecular Imaging, which made its own recommendations to CMS about the agent in March, along with The World Molecular Imaging Society (WMIS) and the American College of Radiology.

All three collaborated with CMS and NOPR upon its launch in 2011 to collect clinical utility data supporting the use of NaF-18 PET. NOPR used applied these findings to more than 65,000 scans it performed on Medicare beneficiaries in that time.

Despite the recommendations and evidence, CMS declined the NOPR request, citing the information provided as insufficient.

"Many seniors may ultimately receive care that is not as effective or helpful as it could be if CMS does not reconsider Medicare coverage for NaF PET,” NOPR co-chair Dr. Anthony Shields said in a statement. “This is a step backward in care for these patients. We urge CMS to reconsider coverage so that these seniors can have access to care that can better help them.”

WMIS, ACR and SNMMI will continue to collaborate with CMS to establish Medicare coverage and access for patients to NaF PET.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2018 DOTmed.com, Inc.
版权所有